EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases

NEW YORK & LONDON--(BUSINESS WIRE)--Eyebiotech Limited (“EyeBio” or “the Company”), a privately held clinical-stage ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases, today announced the successful close of an extension to its Series A financing, bringing the total raised to date to $130 million. EyeBio will use the proceeds from the funding to accelerate the Company’s clinical development program and further build out its innovative retina pi